Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
  1. Homepage
  2. Equities
  3. Netherlands
  4. Euronext Amsterdam
  5. Galapagos NV
  6. Company
    GLPG   BE0003818359

GALAPAGOS NV

(GLPG)
  Report
Real-time Euronext Amsterdam  -  06:42 2022-09-29 am EDT
43.56 EUR   -0.98%
09/27Galapagos increases share capital through subscription right exercises
GL
09/27Galapagos increases share capital through subscription right exercises
AQ
09/09Morgan Stanley Downgrades Galapagos to Equalweight From Overweight, Cuts Price Target to $61 From $80
MT
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
Business Summary
Logo Galapagos NV
Galapagos NV specializes in the research and development of drugs based on novel targets discovered and validated in human primary cells. Net sales break down by source of income as follows:

- sales of collaboration services (97%). Net sales are distributed geographically between Europe (99.6%) and the United States (0.4);

- sales of products (3%).

Number of employees : 1 309 people.
Sales per Business
2021
Upfront Payments and License Fees433.8889.5%
Milestone32.416.7%
Jyseleca14.753%
Royalties3.800.8%
EUR in Million
Sales per region
20202021Delta
United States472.4598.8%467.9899.6% -0.95%
Europe5.611.2%2.110.4% -62.3%
EUR in Million
Managers
Name Title Age Since
Paulus Stoffels Chairman & Chief Executive Officer 60 2022
Bart Filius President, Chief Operating & Financial Officer 52 2021
Walid Abi-Saab Chief Medical Officer 56 2017
Sandra Cauwenberghs, Dr. Director-Investor Relations - 2020
Andre Hoekema, Dr. Chief Business Officer 64 -
Michele Manto Senior Vice President-Commercial Operations - 2017
Phil Dudfield Managing Director-Fidelta - -
Members of the board
Name Title Age Since
Paulus Stoffels Chairman & Chief Executive Officer 60 2022
Howard Mitchell Rowe, Dr. Independent Non-Executive Director 52 2010
Katrine S. Bosley Independent Non-Executive Director 53 2013
Mary Kerr, Dr. Independent Non-Executive Director 60 2016
Peter Guenter Independent Non-Executive Director 59 2019
Lena Elisabeth Svanberg, Dr. Independent Non-Executive Director 60 2020
Jérôme Contamine Independent Director 64 2022
Dan Baker, Dr. Independent Director - 2022
Raj Parekh Director 60 2022
Linda Slanec Higgins, Dr. Non-Executive Director 58 2019
Equities
Vote QuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 65,728,511 48,455,593 73.7% 0 0.0% 73.7%
Shareholders
NameEquities%
Gilead Sciences, Inc. 16,707,477 25.4%
Van Herk Investments BV 4,635,672 7.05%
The Vanguard Group, Inc. 1,434,947 2.18%
Amundi Asset Management SA (Investment Management) 1,220,046 1.86%
Wellington Management Co. LLP 1,184,866 1.80%
T. Rowe Price Associates, Inc. (Investment Management) 1,002,786 1.53%
Norges Bank Investment Management 978,626 1.49%
Federated Global Investment Management Corp. 953,716 1.45%
BlackRock Fund Advisors 837,256 1.27%
Capital Research & Management Co. (World Investors) 797,367 1.21%
Markets and indexes
- Compartiment A
- BEL 20 / AMX, Next 150, Next Biotech, PEA
Stock Exchange Codes
- Bloomberg Code :  GLPG:BB
- Reuters Code :  GLPG.BR
- Datastream Code :  
Company contact information
Galapagos NV
Generaal De Wittelaan L11 A3
BE-2800 Mechelen, Antwerpen

Phone : +32 15 34 29 00
Fax : +32 15 34 29 01
web site : http://www.glpg.com
Brand Portfolio
In partnership withAllbrands.markets
More brands of Galapagos NV